1. Home
  2. BLIN vs BIAF Comparison

BLIN vs BIAF Comparison

Compare BLIN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgeline Digital Inc.

BLIN

Bridgeline Digital Inc.

HOLD

Current Price

$1.01

Market Cap

12.1M

Sector

Technology

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$1.51

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLIN
BIAF
Founded
2000
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
6.6M
IPO Year
2007
2022

Fundamental Metrics

Financial Performance
Metric
BLIN
BIAF
Price
$1.01
$1.51
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$4.62
N/A
AVG Volume (30 Days)
79.6K
87.9K
Earning Date
12-19-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,375,000.00
$6,776,739.00
Revenue This Year
$2.68
N/A
Revenue Next Year
$16.11
$20.04
P/E Ratio
N/A
N/A
Revenue Growth
0.54
N/A
52 Week Low
$0.90
$1.25
52 Week High
$2.80
$46.53

Technical Indicators

Market Signals
Indicator
BLIN
BIAF
Relative Strength Index (RSI) 41.46 40.46
Support Level $0.98 $1.60
Resistance Level $1.12 $1.74
Average True Range (ATR) 0.08 0.12
MACD 0.01 0.05
Stochastic Oscillator 38.41 37.79

Price Performance

Historical Comparison
BLIN
BIAF

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: